First patients dosed in early trial of new cancer drug
NCT ID NCT06493864
Summary
This is a first-in-human study to test the safety and side effects of a new drug called BL-B16D1. It will involve adults with advanced breast cancer or other solid tumors that have spread and cannot be removed by surgery, and who have run out of standard treatment options. The main goals are to find a safe dose and see how the body processes the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.